Pfizer will reportedly ask FDA to approve COVID vaccine for kids under 5
An emergency authorization could be approved within the coming weeks.
Pfizer and its vaccine partner BioNTech are expected as early as Tuesday to ask the US Food and Drug Administration to approve emergency use of its coronavirus vaccine for children 6 months to 5 years old, The Washington Post and The New York Times reported Monday.
Regulators are reportedly asking for data from a two-dose vaccine regimen, potentially leading to approval of an emergency authorization within the coming weeks. The FDA approved Pfizer's COVID-19 vaccine, Comirnaty, for all Americans ages 5 and up in October.
White House medical adviser Dr. Anthony Fauci said in mid-January that a COVID-19 vaccine for children under 5 could be available by the end of February or the beginning of March. Pfizer has been testing a vaccine and booster in children ages 6 months to 5 years old and has said it expects to have more data on the results by April.
Regulators are reportedly eager to review the data from a two-dose vaccine regimen for young children, with hopes of approving an emergency authorization as early as the end of February. But data on the three-shot regimen isn't expected to be available until late March, with regulators' authorization expected soon after of a third dose of the pediatric vaccine.
"We know that two doses isn't enough, and we get that," one unidentified source familiar with the situation told the Post. "The idea is, let's go ahead and start the review of two doses. If the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don't do anything until the third-dose data comes in."
While two doses of a COVID-19 vaccine protect against severe disease and death from COVID-19, boosters are recommended as added protection against the highly contagious omicron variant. Although children as young as 5 can receive Pfizer's two-dose regimen, only teens 16 and up are eligible to receive a booster.
The news comes as the omicron variant is sweeping the globe. It's the dominant strain of COVID in the US, responsible for more than 99% of all new infections, according to the CDC.